Evonik recognised as a leading pharma contract manufacturer

For the fourth year running, Evonik – one of the world’s largest contract development and manufacturing organisations (CDMO) for active pharmaceutical ingredients (APIs) and advanced intermediates – has been recognised as a recipient of the 2021 CMO Leadership Awards across all six categories.

Winners are chosen through market research based on feedback from pharmaceutical companies that utilise outsourcing services. Evonik’s success confirms the company’s outstanding performance and value it brings to the pharmaceutical and life science industries.

As one of the world’s top CMOs for active pharmaceutical ingredients (APIs) and intermediates, the health care business line is part of the life science division Nutrition & Care and represents a key growth lever for Evonik. To meet growing customer demand for its CMO services, Evonik is expanding its production capacity at two sites in Germany, as announced in May 2020.

Recognised and trusted by customers

“To be recognised by our customers as a leader for the fourth time in a row is a tremendous honour,” said Thomas Riermeier, head of Evonik’s health care business line. “This award further validates our position as a preferred development and manufacturing partner for pharmaceutical, biotech and life science companies.”

Life Science Leader magazine and Outsourced Pharma teamed up with Industry Standard Research (ISR) to assess more than 70 CMOs across 23 performance metrics as part of ISR’s 2021 Contract Manufacturing Quality Benchmarking survey of global pharmaceutical and biotechnology companies. For the fourth consecutive year, participating companies voted for Evonik to earn awards for its capabilities, compatibility, expertise, quality, reliability and service.

“We are grateful for the trust our customers place in us every day to manufacture their life-saving APIs and intermediates,” said Andreas Meudt, head of product line exclusive synthesis at Evonik Health Care. “We are committed to continuously expanding our Western-based manufacturing network as well as our portfolio of advanced technologies to maximise supply security and product quality.”

Broad portfolio of advanced technologies

To address the specific needs of large or complex projects, Evonik has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis. These technologies include continuous processes, fermentation, PEGs and mPEGs, catalysts, biocatalysts, cryogenic chemistry and polymer APIs.

For many specialised therapy areas, Evonik serves as a fully-integrated CMO with capabilities to manufacture customised APIs, select and supply functional excipients, develop parenteral or oral formulations, and manufacture finished drug products. In addition to this integrated portfolio of services, many customers are also attracted by Evonik’s reliability and commitment to sustainability.